Functional gastrointestinal disorders: a review of the main provisions of the Rome IV consensus

Cover Page

Cite item

Full Text

Abstract

Objectives – the review presents the analysis of the main changes in Rome IV. The subsequent Rome IV consensus focused on the etiology, pathogenesis, diagnosis and differential diagnosis of the functional gastrointestinal disorders. It updated some definitions of the functional gastrointestinal disorders; opioid-induced constipation was set as a separate disorder; functional abdominal distention was considered specific for functional abdominal bloating as both disorders are often combined and do not replace each other. The functional gastrointestinal disorders still remain of the high medico-social importance as they are endemic, refractory and cause long-term disability.

About the authors

Alexej M. Osadchuk

Samara State Medical University

Author for correspondence.
Email: maxlife2004@mail.ru
ORCID iD: 0000-0002-8488-9235

PhD, Professor, Department of hospital therapy with course of outpatient care and transfusion

Russian Federation, Samara

Igor' L. Davydkin

Samara State Medical University

Email: maxlife2004@mail.ru
ORCID iD: 0000-0003-0645-7645

PhD, Professor, Head of the Department of hospital therapy with course of outpatient care and transfusion

Russian Federation, Samara

Taras A. Gritcenko

Samara State Medical University

Email: maxlife2004@mail.ru
ORCID iD: 0000-0002-2794-5122

PhD, Associate Professor of Department of the hospital therapy with course of outpatient care and transfusion, the hematologist of the 1st Hematology Department in Clinics of SamSMU

Russian Federation, Samara

Igor' V. Kurtov

Samara State Medical University

Email: maxlife2004@mail.ru
ORCID iD: 0000-0003-0420-5735

PhD, Associate Professor of Department of the hospital therapy with course of outpatient care and transfusion, the Head of the 1st Hematology Department in Clinics of SamSMU

Russian Federation, Samara

References

  1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–1407. doi: 10.1053/j.gastro.2016.02.031
  2. Lowell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol. 2012; 10: 712–721. doi: 10.1016/j.cgh.2012.02.029
  3. Palson OS, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. Am J Gastroenterol. 2014 Sep;109(9):1450–60. doi: 10.1038/ajg.2014.181
  4. Patel P, Bercik P, Morgan DG, et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol. 2015;50:816–823. doi: 10.3109/00365521.2015.1007079
  5. Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015 Mar;110(3):444–54. doi: 10.1038/ajg.2015.6
  6. Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399–1407.e2. doi: 10.1053/j.gastro.2015.07.054
  7. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 pluselectrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108:1508–1515. doi: 10.1038/ajg.2013.197
  8. Portila M, Prieto B, Shailubhai K, et al. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. Am J Gastroenterol. 2017 Apr;112(4):613–621. doi: 10.1038/ajg.2016.611
  9. Bajor A, Tornblom H, Rudling M, et al. Increased colonic bile acid exposure: a relevant risk factor for symptoms and treatment in IBS. Gut. 2015;64:84–92. doi: 10.1136/gutjnl-2013-305965
  10. Ford AC, Moayyedi P, Lacy BE, et al. Quigley E.M. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(1):S2–S26. doi: 10.1038/ajg.2014.187
  11. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016 Dec;151(6):1113–1121. doi: 10.1053/j.gastro.2016.08.003
  12. Manheimer E, Wieland LS, Cheng K, et al. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:835–847. doi: 10.1038/ajg.2012.66
  13. Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol. 2010;16:69–75. doi: 10.3748/wjg.v16.i1.69
  14. Chang FY, Chen PH, Wu TC, et al. Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. Asia Pac J Clin Nutr. 2012;21:594–600.
  15. Porter CK, Gormley R, Tribble DR, et al. The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol. 2011;106:130–138. doi: 10.1038/ajg.2010.371
  16. Zhu Y, Zheng X, Cong Y, Chu H, et al. Bloating and distention in irritable bowel syndrome: the role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency. Am J Gastroenterol. 2013; 108:1516–1525. doi: 10.1038/ajg.2013.198
  17. Jiang X, Locke GR, Choung RS, et al. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut. 2008;57:756–763. doi: 10.1136/gut.2007.142810
  18. Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioidinduced constipation: a systematic review. J Clin Gastroenterol. 2015;49:9–16. doi: 10.1097/MCG.0000000000000246
  19. Viscusi ER. Clinical overview and considerations for the management of opioid-induced constipation in patients with chronic noncancer pain. Clin J Pain. 2019 Feb;35(2):174–188. doi: 10.1097/AJP.0000000000000662

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Osadchuk A.M., Davydkin I.L., Gritcenko T.A., Kurtov I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).